S-TARget therapeutics develops therapeutic vaccines to cure and prevent severe allergic diseases.
S-TARget therapeutics GmbH is a biotech start-up company founded in September 2010, that develops novel therapeutic vaccines to cure and prevent allergic diseases.
S-TARget‘s vaccines are based on the human specific, unique, proprietary S-TIR™ technology platform that addresses the cause of the disease not only the symptoms. The vaccines are directed against major, widespread allergic diseases that currently cannot be cured – including severe forms of allergy. Lead candidate SG100 targets allergic asthma induced by house dust mite (HDM), the major cause of allergy in the Western world.